The wellness world is eager for RFK Jr.'s promised move on peptides
The US wellness community is awaiting a potential move by Health Secretary Robert F. Kennedy Jr. to loosen restrictions on certain unapproved peptide therapies. The FDA currently prohibits compounding pharmacies from making these peptides due to safety concerns and lack of data, but a change in status could allow consumers to access them from regulated suppliers.
Health Secretary Robert F. Kennedy Jr. has signaled that the FDA may change the status of certain peptides, allowing consumers to access them from regulated suppliers. Peptides are strings of amino acids that can be used for tissue repair, skin health, and longevity. Currently, the FDA prohibits compounding pharmacies from making these peptides due to safety concerns and lack of data. The peptides in question are not approved drugs and have largely not been tested for safety or efficacy in human trials. Proponents argue that they have a better safety profile because they are known compounds that the body already makes. However, experts warn that without rigorous testing, the compounds could have unintended harmful effects.
This content was automatically generated and/or translated by AI. It may contain inaccuracies. Please refer to the original sources for verification.